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ABSTRACT

Wagle, JP, Carroll, KM, Cunanan, AJ, Wetmore, A, Taber, CB,
DeWeese, BH, Sato, K, Stuart, CA, and Stone, MH. Preliminary investigation into the effect of ACTN3 and ACE polymorphisms on muscle and performance characteristics. J
Strength Cond Res XX(X): 000–000, 2018—The purpose of
this investigation was to explore the phenotypic and performance outcomes associated with ACTN3 and ACE polymorphisms. Ten trained men (age = 25.8 6 3.0 years, height =
183.3 6 4.1 cm, body mass = 92.3 6 9.3 kg, and back squat
to body mass ratio = 1.8 6 0.3) participated. Blood samples
were analyzed to determine ACTN3 and ACE polymorphisms.
Standing ultrasonography images of the vastus lateralis (VL)
were collected to determine whole muscle cross-sectional area
(CSA-M), and a percutaneous muscle biopsy of the VL was
collected to determine type I–specific CSA (CSA-T1), type II–
specific CSA (CSA-T2), and type II to type I CSA ratio (CSAR). Isometric squats were performed on force platforms with
data used to determine peak force (IPF), allometrically scaled
peak force (IPFa), and rate of force development (RFD) at
various timepoints. One repetition maximum back squats were
performed, whereby allometrically scaled dynamic strength
(DSa) was determined. Cohen’s d effect sizes revealed
ACTN3 RR and ACE DD tended to result in greater CSA-M
but differ in how they contribute to performance. ACTN3 RR’s
influence seems to be in the type II fibers, altering maximal
strength, and ACE DD may influence RFD capabilities through
a favorable CSA-R. Although the findings of the current investigation are limited by the sample size, the findings demon-
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strate the potential influence of ACTN3 and ACE
polymorphisms on isometric and dynamic strength testing. This
study may serve as a framework to generate hypotheses
regarding the effect of genetics on performance.

KEY WORDS fiber type, genetics, genotype, muscle size,
strength, rate of force development

INTRODUCTION

A

thletic potential and performance outcomes are
believed to be the result of a combination of several factors related to training and recovery strategies. Genotype, however, is likely the largest
contributor to athletic potential and performance, with heritability estimated to be responsible for as much as 66% of
performance (7). Human gene mapping has been especially
insightful in the identification of candidate genes related to
certain phenotypic characteristics. Two of the most extensively explored in athletics are the a-actinin-3 (ACTN3) and
angiotensin-converting enzyme (ACE) genes.
ACTN3 encodes for the skeletal muscle a-actinin-3, which
is expressed predominantly in sarcomeres of fast-twitch, glycolytic muscle fibers (8,16). The expressed protein is believed
to enhance structural integrity of the Z-line within these
sarcomeres, consequently enhancing its force production capabilities. A polymorphism of the ACTN3 gene that may
influence the performance outcomes occurs at amino acid
577 (16). The replacement of arginine (R) with a stop codon
(X) at that location within chromosome 11 creates the most
notable gene variants pertaining to strength-power performance outcomes (6). The R allele and the RR polymorphism
have well-established relationships to strength-power performance outcomes in a variety of populations, including soccer
players (24), rowers (6), and sprinters (21). Furthermore,
in ACTN3 knockout mouse models, a decreased fiberVOLUME 00 | NUMBER 00 | MONTH 2018 |
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specific cross-sectional area (CSA) was observed in type II
fibers with a concomitant reduction in strength (17).
ACE has several polymorphic sites, but of interest are
the presence (insertion, I allele) or absence (deletion, D
allele) of a 287-base pair (bp) Alu element fragment at
intron 16. Fragment absence, the D allele, has been most
associated with strength-power related phenotype (13),
particularly in sprinters (20). This may be due to the
increased localized ACE activity within the muscle
observed in the presence of the D allele, ultimately leading
to a greater conversion of angiotensin I to angiotensin II.
A greater amount of angiotensin II has been associated
with cell growth in endothelial, cardiac, and vascular
smooth muscle cells. Because of the recently increasing
evidence of localized renin-angiotensin systems within
the muscle, it is possible that the D allele is associated
with increased muscle growth, which would be advantageous for strength-power athletes (5).
The observed outcomes of certain ACTN3 and ACE polymorphisms within the context of sport performance primarily address prevalence within certain athletic populations
and the implications for talent identification. Few studies
address the specific effects of polymorphisms on mechanistic
strength-related characteristics (9,10). Although valuable,
these investigations often focused on the untrained (3,9,10)
or elderly (19). Therefore, there is a gap in the current literature exploring the potential effect of various polymorphisms of these 2 candidate genes have on mechanistic
physical outputs—especially considering trained, strong subjects. Furthermore, to the authors’ knowledge, no study has
simultaneously examined the influence that ACTN3 and
ACE polymorphisms have on muscle characteristics. Therefore, the purpose of this investigation was to explore the
phenotypic physiological and performance outcomes associated with the respective ACTN3 and ACE polymorphisms
in trained subjects. Specifically, the authors aimed to provide
a rationale for further investigation of (a) the potential effect
that ACTN3 and ACE polymorphisms have on whole muscle and fiber-specific characteristics and (b) the effect that
ACTN3 and ACE polymorphisms have on isometric and
dynamic performance capabilities.

METHODS
Experimental Approach to the Problem

To explore the phenotypic physiological and performance
outcomes associated with ACTN3 and ACE polymorphisms,
subjects were asked to complete a testing series beginning
with a whole blood draw, which would eventually be used
for genotyping. Immediately thereafter, subjects completed
standing ultrasonography measurements and a one-time
subcutaneous muscle biopsy—both of the vastus lateralis
(VL). After 48 hours of rest, subjects returned to complete
isometric squat (ISQ) testing performed on dual force platforms to assess isometric strength and rate of force development (RFD) capabilities. Finally, subjects completed a 1

2
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repetition maximum (1RM) back squat after another 48hour rest period.
Subjects

Ten well-trained men (mean 6 SD; age = 25.8 6 3.0 years,
height = 183.3 6 4.1 cm, body mass = 92.3 6 9.3 kg, and
back squat to body mass ratio = 1.8 6 0.3) volunteered for the
current investigation. Subjects, most of whom were former
athletes including Division I and professional status, were
required to have spent at least the past year engaging in
a strength training program that included back squats. Each
subject’s hydration status (urinary specific gravity) was determined using a refractometer (Atago, Tokyo, Japan) before any
data collection to ensure that hydration status would not
influence the results. All subjects read and signed a written
informed consent form, and the procedures were approved by
East Tennessee State University’s Institutional Review Board.
Procedures

Genotyping. A 10-ml blood sample was drawn into 2 separate
4-ml EDTA tubes (BD Vacutainer K2 EDTA; Franklin Labs,
NJ, USA) by venipuncture from certified personnel. The
whole blood samples were stored at 2808 C until subsequent
analysis. Automated DNA extraction was performed using
the manual processing protocol of the QIAamp DNA Blood
Mini Kit (Qiagen, Crawley, United Kingdom). Real-time
polymerase chain reaction (PCR) was performed to determine the genotype of the ACTN3 and ACE polymorphisms
in each subject, with reactions performed on 96-well microtiter plates. Each 50 ml of reaction volume contained 25-ml
Platinum Superfi PCR Master Mix (ThermoFisher, Waltham, MA, USA), 10-ml 5X Superfi GC Enhancer (ThermoFisher, Waltham, MA, USA), 2.5 ml of both the respective
forward and reverse primers for ACTN3 and ACE, and 12.5
ml of subject DNA combined with nuclease-free water at
a concentration of approximately 250 ng$ml21.
For ACTN3, the 290-bp fragment of exon 15 was amplified
using the forward primer CTGTTGCCTGTGGTAAGTGGG
and the reverse primer TGGTCACAGTATGCAGGAGGG.
Polymerase chain reaction was performed for 35 cycles (30
seconds of denaturation at 948 C, 30 seconds of annealing at
658 C, and 60 seconds of extension at 728 C), final extension at
728 C for 5 minutes, and held at 48 C. Amplified products were
then electrophoresed on 0.5% agarose gel stained with ethidium
bromide to confirm primer adherence. Samples were then purified using QIAquick PCR Purification Kit (Qiagen, Calgary,
United Kingdom). After purification, ACTN3 polymorphisms
were determined using an automated DNA sequencer (CEQ
8000 Genetic Analysis System; Beckman Coulter, Indianapolis,
IN, USA).
The ACE PCR amplification followed identical procedures of
those used for ACTN3 except for the substitution of specific
primers for ACE—the forward primer CTGGAGACCACTCCCATCCTTTCT and reverse primer GATGTGGCCATCACATTCGTCAGA. To determine polymorphism, amplified
products were electrophoresed and visualized by using agarose
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gels stained with ethidium bromide. The products were assessed
for the presence of a 490 bp fragment (I allele), a 190 bp fragment (D allele), or both (I/D heterozygote) (Figure 1). Genotyping was performed in accordance with published genotyping
and quality control recommendations including external control
samples and internal controls of genotyping samples in duplicates (23,29).
Standing Ultrasonography Measurement. Standing ultrasonography measures began with the application of a watersoluble transmission gel to the measurement site and
a 16-Hz probe oriented in the short-axis, perpendicular to
the VL muscle, while not depressing the skin. Subjects were
upright and bearing weight on the opposite leg, which was
positioned on a 5-cm tall platform, unweighting the measured leg and creating an internal knee angle of 160 6 108
(30). Cross-sectional area (CSA-M) was obtained using
a panoramic image sweep in the transverse plane perpendicular to the muscle (31). A straight-edge was placed along the
skin to ensure that the probe remained along the previously
established midline. Three images were obtained and saved
for subsequent analysis using the software provided within
the ultrasonography device.
Muscle Biopsy Sampling and Processing. Immediately after
ultrasonography and blood draw procedures, all subjects
received a one-time percutaneous biopsy. Biopsies of the
superficial region of right VL at a depth of approximately 3
cm were obtained using the Bergström (2) technique and
a 5-mm biopsy needle with suction with 1% lidocaine as
a local anesthetic. A portion of the muscle tissue was immediately mounted on cork under a microscope to orient the
specimen for transverse sectioning, frozen in a slurry of isopentane cooled by liquid nitrogen, and stored at 2808 C
until subsequent processing. The samples were sectioned
on a cryostat (Leica, Wetzlar, Germany) at a thickness of

Figure 1. ACE polymorphism results by subject.
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14 mm and affixed to a microscope slide in preparation for
immunohistochemical analysis.
After sectioning and mounting, tissues were fixed with
acetone at 2208 C for 2 sets of 5 minutes each. All samples
were then blocked for 2 hours in a 10% normal goat serum.
Sections were incubated overnight in monoclonal antibodies
specific to myosin heavy chain (MYH) isoforms: MYH2 for
type IIA fibers (IgG1, 1:100 dilution) and MYH7 for type I
fibers (IgG2b, 1:200 dilution) (Developmental Studies
Hybridoma Bank; University of Iowa, Iowa City, IA, USA).
Finally, samples were then incubated for 2 hours using goat
antimouse AlexaFluor 350 (IgG1) and AlexaFluor 555
(IgG2b), each at 1:200 dilution (Invitrogen, Carlsbad, CA,
USA).
A series of photographs were taken of the slides at 310
magnification using an Olympus BX41 microscope (Olympus
America, Inc., Melville, NY) and imaged using an Olympus
Q-Color3 camera (Olympus America, Inc., Melville, NY).
Fibers were classified, counted, and sized using the ImageJ
software (National Institute of Health, USA). Using the color
composite feature within the software, fiber types were identified and sized objectively based on the color-specific staining intensity within each. Type I–specific CSA (CSA-T1),
type II–specific CSA (CSA-T2), and type II to type I CSA
ratio (CSA-R) were calculated from the collected data.
Isometric Strength Assessment. Subjects completed a standardized general warm-up sequence before beginning the isometric strength assessment. Isometric strength was assessed
using the ISQ using an adapted protocol from McBride et al.
(18). Subject bar heights were set such that an internal knee
angle of 1008 existed, which was assessed through goniometer (18). Data were collected using a dual force platform
design (2 3 91 cm 3 45.5 cm of force platforms; RoughDeck
HP, Rice Lake, WI, USA) inside a custom-built apparatus
with data sampled at 1,000 Hz.
Participants completed warm-up trials at 50 and 75% of
their perceived maximal effort before performing a minimum
of 2 maximal effort trials. If a countermovement of greater
than 200 N was observed, or trials differed by more than 250
N, subjects were required to complete an additional trial (15).
Participants were also instructed to push “as fast and hard as
possible” and were strongly verbally encouraged during trials
(18). A 3-minute seated rest interval was prescribed between
each of the ISQ trials. LabVIEW (Version 7.1; National Instruments, Austin, TX, USA) was used for collecting and
ForceDecks (Version 1.2.6464; NMP Technologies Ltd., London, United Kingdom) for processing kinetic data (4). Peak
force (IPF), allometrically scaled peak force (IPFa), and RFD
over 50 ms (RFD-50), 100 ms (RFD-100), and 200 ms (RFD200) were calculated from the collected data.
Dynamic Strength Assessment. Dynamic strength was measured using a 1RM back squat. Dynamic strength testing was
completed after ISQ and after 48 hours of rest to ensure that
VOLUME 00 | NUMBER 00 | MONTH 2018 |
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*CSA-M = whole muscle cross-sectional area; CSA-T1 = type I fiber cross-sectional area; CSA-T2 = type II fiber cross-sectional area; CSA-R = type II to type I cross-sectional
area ratio; IPF = peak force; IPFa = allometrically scaled peak force; RFD-50 = rate of force development at 50 ms; RFD-100 = rate of force development at 100 ms; RFD-200 = rate
of force development at 200 ms; 1RM = 1 repetition maximum back squat; DSa = allometrically scaled dynamic strength.
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All performance-dependent variables in the current investigation returned acceptable ICC values (11). The frequency of
RR, RX, and XX ACTN3 genotypes was 70% (n = 7), 30% (n
= 3), and 0% (n = 0), respectively. The frequency of DD, ID,
and II ACE genotypes was 30% (n = 3), 50% (n = 5), and
20% (n = 2), respectively (Figure 1).
A moderate between-group effect (d = 0.61) favored
ACTN3 RR compared with ACTN3 RX for CSA-M. In addition, a small between-group effect favored ACTN3 RR for
CSA-T1 (d = 0.21), CSA-T2 (d = 0.42), and CSA-R (d =
0.58). Isometric and dynamic performance outcomes also
favored ACTN3 RR over ACTN3 RX, yielding moderate
between-group effect magnitudes for IPF (d = 0.73), IPFa
(d = 0.94), RFD-200 (d = 0.64), and 1RM (d = 0.99), along
with a large effect for DSa (d = 1.51) (Table 1).
A moderate between-group effect for CSA-M favored
ACE DD compared with ACE ID (d = 0.67) and ACE ID
over ACE II (d = 0.65), along with a large positive effect in
ACE DD over ACE II (d = 1.37). A moderate unfavorable
effect for CSA-T1 was observed in ACE ID compared with
ACE DD (d = 20.83) and ACE II compared with ACE DD
(d = 20.80)—meaning that CSA-T1 was smallest in ACE
DD. Conversely, small effects were present favoring ACE

CSA-M

RESULTS

Muscle characteristics

Subjects were grouped by polymorphism for both ACTN3
and ACE for analysis. Descriptive statistics including mean
and SD were calculated. Within-subject reliability for each
variable was assessed using intraclass correlation coefficients
(ICCs) (12). Between-group Cohen’s d effect sizes were calculated for each dependent variable to determine the magnitude and meaningfulness of performance differences across
polymorphisms. Effect sizes were interpreted with magnitude thresholds of 0–0.2, 0.2–0.6, 0.6–1.2, 1.2–2.0, and 2.0
and above as trivial, small, moderate, large, and very large
(11). Statistical analyses were performed using Microsoft
Excel (Redmond, WA, USA).

TABLE 1. Between-group Cohen’s d effect size and the corresponding practical interpretation.*

Statistical Analyses

IPFa

Performance characteristics

1RM

DSa

subjects were adequately recovered. Before testing, each
subject performed a general dynamic warm-up.
After the general warm-up, bar and safety bar heights in
the squat rack were adjusted as needed to best accommodate
each subject. Subjects warmed up with progressively heavier
loads of 30, 50, 70, 80, and 90% of their self-reported 1RM
for 5, 3, 2, 1, and 1 repetitions, respectively, before maximal
attempts. Each subject attained their 1RM back squat by
attempting progressively heavier loads until they could not
complete a successful repetition. For a repetition to be
considered successful, the subject’s hip crease must have
been below the patella at the bottom of the descent during
the back squat and was verified by multiple certified strength
and conditioning coaches. One repetition maximum back
squat and allometrically scaled dynamic strength (DSa) were
calculated from the collected data.

1.51
Large
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ID over ACE II (d = 0.35) in CSA-T1. ACE DD had a moderate effect difference over ACE II in CSA-R (d = 0.88).
Furthermore, large favorable effects were present comparing
ACE DD with ACE ID in CSA-R. (d = 1.42). Trivial effects
were observed comparing all ACE polymorphisms for CSAT2 (Table 1). Considering ACE DD with respect to ACE ID,
a moderate favorable effect was observed for IPF (d = 0.70),
1RM (d = 1.14), and DSa (d = 1.06). ACE ID had a moderate
favorable effect for RFD-100 (d = 0.69) relative to ACE II.
Finally, moderate effects favored ACE DD over ACE II in
RFD-100 (d = 0.66), 1RM (d = 0.93), and DSa (d = 0.62).

DISCUSSION
The purpose of this investigation was to explore the
potential physiological and performance outcomes associated with ACTN3 and ACE polymorphisms. Specifically, the
authors aimed to examine (a) the potential effect that
ACTN3 and ACE polymorphisms have on muscle characteristics including whole muscle, fiber-specific morphology
and fiber-specific CSA distribution and (b) the effect that
ACTN3 and ACE polymorphisms have on isometric and
dynamic performance capabilities. The main results of this
investigation have shown that subjects possessing the
ACTN3 RR polymorphism had larger whole muscle and
fiber-specific CSA as well as a greater CSA-R compared with
ACTN3 RX. Furthermore, our results indicate that individuals with the ACTN3 RR variant were stronger under both
isometric and dynamic conditions and may possess greater
RFD capabilities. Although ACE DD had the largest whole
muscle CSA, a moderate between-group effect favored ACE
ID and ACE II variants for CSA-T1. However, no meaningful effects were observed for CSA-T2.
Whole muscle CSA, often used as an indicator of force
production capabilities (26), is affected by both inherited
(i.e., candidate gene polymorphism) and environmental factors (i.e., training and nutrition). Because of the a-actinin-3
protein’s role as an actin anchor within the Z-line of fast
muscle and ACE’s role in the synthesis of angiotensin II
and cell growth, both provide mechanistic rationale for
a larger muscle phenotype. The ACTN3 R allele has been
associated with larger whole muscle size in previous literature (32), which agrees with the findings of the current investigation. However, Zempo et al. (32) compared the presence
of the R allele (i.e., ACTN3 RR and RX) with ACTN3 XX. In
the current investigation, no X allele homozygotes were
present, but the findings do reveal the potential that R allele
homozygotes (ACTN3 RR) possess a greater whole muscle
size in comparison with heterozygotes (ACTN3 RX).
The ACE DD polymorphism presents a less clear mechanistic rationale as it relates to muscle size (10), although
previous literature has indicated that the D allele is associated with greater changes in muscle CSA after resistance
training (23). It has been postulated that, because there is
a high prevalence of ACE within the muscle, that the generation of angiotensin II (a potent growth regulator in car-
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diac and smooth muscle) provides a link to larger muscle
sizes. The presence of the ACE II genotype has been associated with high-level endurance performance (20), which
typically favors athletes with lesser muscle mass than
strength-power athletes (1). In addition, previous longitudinal research has suggested a preference for ACE DD and
ACE ID variants for the gaining of muscle mass over ACE II
(5). Indeed, the results of the current cross-sectional investigation indicated that muscle mass was from greatest-to-least:
ACE DD . ACE ID . ACE II. Although training, nutrition,
and other factors may ultimately determine the muscle size
as an adult, the presence of one or both polymorphisms may
provide for a greater potential for muscle hypertrophy, and
therefore a greater force production capability.
Strength potential is also closely related to the composition of the muscle. This includes fiber-type specific CSA and
the CSA-R. The current investigation provided interesting
considerations in this regard, demonstrating the potential
that ACTN3 RR may have a small effect on both CSA-T1
and CSA-T2 compared with ACTN3 RX. The ACTN3 RR
genotype has been linked to elite strength-power performance in track and field (22,25). Therefore, the findings of
the current investigation lend support for previous findings,
especially considering ACTN3’s function within fast, glycolytic fibers. Interestingly, the ACE DD genotype was associated with a moderate decrease in CSA-T1 compared with
the other genotypes and no effect in CSA-T2. However,
there was a small between-group effect favoring ACE DD
over ACE ID and a moderate effect supporting ACE DD
over ACE II, which creates a potentially favorable scenario
for force production abilities. Considering the potential combination of ACTN3 RR (i.e., larger CSA-T2) and ACE DD
(i.e., smaller CSA-T1), there may be a situation where the
CSA-R may be maximized. Greater CSA-R may minimize
the drag effect that T1 fibers have on T2 fibers during whole
muscle contraction, potentially increasing the maximum
contraction velocity (14,28). A higher contraction velocity
would be beneficial to performances in strength-power
events, particularly in sprinting and jumping, which involve
high RFDs and dynamic strength.
The ACTN3 RR and ACE DD genotypes were simultaneously present in 2 subjects in the current investigation.
Although there are technical limitations of only having 2
subjects with these genotypes simultaneously, it is interesting
to note that these subjects yielded among the greatest scores
on isometric and dynamic strength as well as RFD. More
specifically, one of the subjects had the highest CSA-M,
greatest CSA-R, and ranked first in each performance measure collected including absolute and relative measures of
strength performance and RFD at all considered timepoints.
The other subject possessing both genotypes had the second
highest CSA-M, was second in 1RM, third in IPF and DSa,
and fourth in IPFa. The RFD capabilities of the second subject increased in rank as the timepoint expanded, moving
from seventh in RFD-50 up to fourth in RFD-200 among
VOLUME 00 | NUMBER 00 | MONTH 2018 |
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all subjects. The lower ranking in the early RFD timepoints
may be partly due to this subject’s seventh-ranked CSA-R,
which has been previously connected to RFD capabilities
(28). This variability in RFD may indicate the importance
of training, as the subjects had different athletic backgrounds.
It may also suggest that there are other genes and their
respective polymorphisms that must be taken into consideration that more drastically influence RFD capabilities than
ACTN3 and ACE. This list may contain more than 40 candidate genes (27) including, but not limited to MCT1 (monocarboxylate transport 1), MYLK (myosin light chain kinase),
COL1-A1 (collagen a-1 chain type I), insulin-like growth
factor–related genes, or myostatin-related genes (27). As
demonstrated, the factors influencing strength performance
are robust and comprise bioenergetic, structural, and regulatory aspects.
Although the findings of the current investigation are
limited by the sample size, it is the first of the authors’
knowledge to investigate the potential influence of ACTN3
and ACE polymorphisms on isometric and dynamic
strength testing. This research has the potential to act as
a framework for the generation of future hypotheses within
strength and conditioning research as it relates to the influence of genetics. The current investigation suggests that the
ACTN3 RR and ACE DD tend to result in greater whole
muscle size but differ in how they contribute to performance
capacities. While ACTN3 RR’s influence seems to be in the
T2 fibers and therefore alters gross isometric and strength
performance, ACE DD seems to influence RFD capabilities
through creating a favorable CSA-R. Future investigations
should continue to explore the individual and combined
effects of these 2 genotypes as well as the inclusion of other
heritable characteristics and their relative contributions to
performance potential and outcomes.

The findings of the current investigation provide unique
considerations for talent identification of strength-power
athletes. Although previous investigations have explored
the general physical qualities associated with these 2
candidate genes and their respective polymorphisms, the
current investigation is the first to provide specific effect
magnitudes on mechanistic strength qualities, albeit with
a limited sample size. This may be valuable for organizations and governing bodies with long-term athlete
development models that guide younger athletes toward
certain sports in which they have a higher likelihood for
success.
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